
Crane Company (CR) Stock Forecast & Price Target
Crane Company (CR) Analyst Ratings
Bulls say
Crane demonstrated robust financial performance in 2025, with total revenues reaching approximately $2.3 billion, driven by a notable 5.6% year-over-year increase in organic sales and a 16% rise in organic backlog, totaling $1.44 billion. The company's aerospace and advanced technologies segment benefitted from significant orders in the cryogenic business and expanding opportunities in military and power infrastructure sectors, highlighting its diverse growth drivers. Furthermore, ongoing strategic initiatives, including a major pharmaceutical order related to capacity expansion and advancements in technology capabilities, position Crane favorably for sustained market outgrowth and profitability.
Bears say
Crane's quarter-end backlog of $1.44 billion reflects a mixed performance, with a strong 17% year-over-year increase countered by a 2% decline within the Process Flow Technologies (PFT) segment, indicating weakening demand, particularly in the chemical market. The firm's 2026 core growth assumptions have been adjusted downward due to a lackluster start in PFT, driven by slow order bookings in late 2025, particularly in Europe and APAC. Additionally, despite a raised guidance midpoint for earnings per share, projections still fall short of both internal models and consensus estimates, indicating potential revenue challenges ahead.
This aggregate rating is based on analysts' research of Crane Company and is not a guaranteed prediction by Public.com or investment advice.
Crane Company (CR) Analyst Forecast & Price Prediction
Start investing in Crane Company (CR)
Order type
Buy in
Order amount
Est. shares
0 shares